Doctor of Philosophy, Case Western Reserve University, 2025, Pathology
Plasmodium vivax induces blood stage infections by invading red blood cells (RBCs) using the Duffy (Fy) blood group antigen system. Individuals with the Fy blood group-positive alleles (FY*A and/or FY*B) are susceptible to infection, while Fy-negative (null) individuals with the erythrocyte silent, ES, allele (FY*AES and FY*BES) show resistance. Recent studies challenge this paradigm by reporting that Fy null populations across sub-Saharan Africa show incidences of P. vivax infection. In addition, our recent breakthrough discovery in Cell Host Microbe demonstrates Fy “null” cells may in fact express the Fy protein. Studies suggest that sites of hematopoiesis, such as the bone marrow or spleen, may act as a biological niche for P. vivax invasion into reticulocytes (the parasite's preferred target cells), but this has not been substantiated in vivo. To investigate this, a reliable culturing protocol and method of assessment is required. Research shows that culturing P. vivax in vitro is not only challenging, but impossible on a long-term scale, necessitating more innovative methods. We demonstrate that human bone marrow can be utilized to culture P. vivax and propagate the parasite on a long-term basis (over 1 year) for a series of experiments. To address our limitations, we have introduced the more easily cultured P. knowlesi (the closest related Plasmodium species to P. vivax) that has been genetically modified to replace its endogenous Fy binding protein (DBP) orthologue with PvDBP to create a transgenic parasite, PkPvDBPOR. Using this model, we evaluated the culture under different perturbations (e.g. Fy-specific antibodies) and discovered low level in vitro invasion of Fy null recipient cells.
Committee: Peter Zimmerman (Advisor); Brian Cobb (Committee Chair); Nicholas Ziats (Committee Member); Christopher King (Committee Member); Jürgen Bosch (Committee Member)
Subjects: Biology; Biomedical Research; Immunology; Microbiology; Parasitology